dry eye disease

Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study
Fierce Biotech
Thu, 08/8/24 - 10:25 pm
Aldeyra Therapeutics
dry eye disease
reproxalap
FDA
Palatin CEO claims ‘a positive study on its face,’ despite dry eye drug's primary endpoint miss
Fierce Biotech
Wed, 02/28/24 - 10:49 am
Palatin Technologies
dry eye disease
PL9643
clinical trials
Alcon’s dry eye drug achieves primary endpoints in Phase III trials
Clinical Trials Arena
Wed, 01/10/24 - 09:42 am
Alcon
dry eye disease
FDA
clinical trials
AR-15512
FDA Rejects Aldeyra’s Dry Eye Drug, Cites Need for Additional Trial
BioSpace
Wed, 11/29/23 - 12:03 pm
Aldeyra Therapeutics
reproxalap
FDA
dry eye disease
Aldeyra Anticipates FDA Rejection of Dry Eye Drug Following Regulatory Meeting
BioSpace
Tue, 10/17/23 - 10:17 am
Aldeyra Therapeutics
dry eye disease
reproxalap
FDA
Bausch + Lomb Buys J&J’s Dry Eye Drops for $106.5M in Expansion of OTC Business
BioSpace
Thu, 07/6/23 - 11:32 am
Bausch + Lomb
dry eye disease
OTC
JNJ Vision
Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis
Healio
Fri, 06/30/23 - 10:10 am
Bausch + Lomb
M&A
Novartis
Xiidra
dry eye disease
FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug
BioSpace
Fri, 05/19/23 - 10:23 am
Bausch + Lomb
Novaliq
Miebo
FDA
dry eye disease
Aldeyra reports positive data from dry eye disease therapy trial
Clinical Trials Arena
Wed, 03/1/23 - 10:08 am
Aldeyra Therapeutics
clinical trials
reproxalap
dry eye disease
Aldeyra’s sights set on November PDUFA
Endpoints
Tue, 02/7/23 - 11:57 am
Aldeyra Therapeutics
dry eye disease
reproxalap
FDA
Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug
Medical Dialogues
Wed, 01/4/23 - 09:41 am
Aurinia Pharmaceuticals
Sun Pharma
dry eye disease
Cequa
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Fierce Biotech
Tue, 09/6/22 - 10:41 am
Iveric Bio
Apellis Pharmaceuticals
clinical trials
FDA
dry eye disease
geographic atrophy
Oyster Point plows ahead with 50 layoffs to focus on approved eye drug
Fierce Biotech
Fri, 08/12/22 - 10:26 am
Oyster Point Pharma
layoffs
dry eye disease
Aldeyra says eye drop clears three dry eye signals en route to FDA
Endpoints
Tue, 07/12/22 - 10:51 am
Aldeyra Therapeutics
dry eye disease
FDA
clinical trials
reproxalap
Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch
BioSpace
Thu, 06/30/22 - 11:05 am
Oyster Point Pharma
layoffs
dry eye disease
Tyrvaya
Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA
BioSpace
Thu, 06/9/22 - 10:22 am
Aldeyra Therapeutics
dry eye disease
reproxalap
clinical trials
With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market
MedCity News
Tue, 03/8/22 - 10:01 am
AN2 Therapeutics
Okyo Pharma
IPOs
clinical trials
lung disease
dry eye disease
Aldeyra builds case for troubled dry eye drug reproxalap
Pharmaforum
Wed, 01/12/22 - 10:52 am
Aldeyra Therapeutics
dry eye disease
reproxalap
Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
Motley Fool
Sat, 10/30/21 - 10:50 pm
Pfizer
Chantix
dry eye disease
Oyster Point Pharma
FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease
Endpoints
Mon, 10/18/21 - 11:57 am
Oyster Point Pharma
Tyrvaya
FDA
dry eye disease
Chantix

Pages